DEVELOPMENT AND APPROBATION METHOD OF IDENTIFICATION MUTATIONS THE RESISTANCE OF THE HEPATITIS C VIRUS TO DIRECT-ACTING ANTIVIRAL AGENTS (DAAs)

Código QR

DEVELOPMENT AND APPROBATION METHOD OF IDENTIFICATION MUTATIONS THE RESISTANCE OF THE HEPATITIS C VIRUS TO DIRECT-ACTING ANTIVIRAL AGENTS (DAAs)

.

Guardado en:

Detalles Bibliográficos
Autores principales:	D. E. Valutite, Yu. V. Ostankova
Formato:	article
Lenguaje:	RU
Publicado:	Sankt-Peterburg : NIIÈM imeni Pastera 2018
Materias:	Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/5680a9f4462648e5af00a862416afcae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

CHALLENGES AND PERSPECTIVES IN HEPATITIS C VIRUS (HCV) RESEARCH IN AN ERA OF DIRECT ACTING ANTIVIRAL (DAA) THERAPY
por: A. Budkowska
Publicado: (2018)

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.
por: Fei Xiao, et al.
Publicado: (2014)

HEPATITIS B VIRUS IDENTIFICATION IN THE ENSURING INFECTIOUS SAFETY OF BLOOD TRANSFUSIONS
por: Yu. V. Ostankova, et al.
Publicado: (2018)

THE DRUG RESISTANCE MUTATIONS OF THE HEPATITIS B VIRUS AMONG HIV-INFECTED INDIVIDUALS
por: Yu. V. Ostankova
Publicado: (2018)

THE PREVALENCE OF HIV-1 DRUG RESISTANCE MUTATIONS IN PATIENTS WITH LOW ADHERENCE TO ANTIRETROVIRAL THERAPY IN THE LENINGRAD REGION
por: A. N. Shchemelev, et al.
Publicado: (2018)

THE SIGNIFICANCE OF THE HIV RESISTANCE ANALYSIS IN ANTIRETROVIRAL THERAPY
por: D. E. Valutite, et al.
Publicado: (2018)

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
por: Kamal SM
Publicado: (2014)

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
por: Vicente Soriano, et al.
Publicado: (2022)

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
por: Irina RUSU, et al.
Publicado: (2020)

Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment
por: María E. Cárdaba-García, et al.
Publicado: (2021)

Effect of different direct-acting antiviral regimens for treatment of nondiabetic hepatitis C virus–infected Egyptian patients on insulin resistance and sensitivity
por: Tarek Yosef, et al.
Publicado: (2021)

Effects of Hepatitis C Virus Elimination by Direct-Acting Antiviral Agents on the Occurrence of Oral Lichen Planus and Periodontal Pathogen Load: A Preliminary Report
por: Yumiko Nagao, et al.
Publicado: (2021)

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
por: Kao-Chi Chang, et al.
Publicado: (2021)

A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy
por: Cesare Mazzaro, et al.
Publicado: (2021)

Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
por: Tag-Adeen M, et al.
Publicado: (2017)

Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients
por: V. Stalin Raj, et al.
Publicado: (2017)

Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan
por: Chun-Ming Hong, et al.
Publicado: (2021)

‘Real-life’ experience with direct-acting antiviral agents for HCV after kidney transplant
por: Fabrizio Fabrizi, et al.
Publicado: (2021)

EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
por: Arif Qayyum Khan, et al.
Publicado: (2020)

EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
por: Arif Qayyum Khan, et al.
Publicado: (2020)

Experimental approbation of an electrodynamic direct electric system for external automobile body repair
por: A.Yu. Bondarenko, et al.
Publicado: (2014)

DEPENDENCE OF THE PHENOTYPIC COMPOSITION OF T-LYMPHOCYTES IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C ON THE VIRUS GENOTYPE (IN DYNAMICS OF TREATMENT OF MEDICINES OF DIRECT ANTIVIRAL ACTION)
por: A. Borisov, et al.
Publicado: (2019)

Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain
por: Abdulla M, et al.
Publicado: (2019)

A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.
por: Bambang S Adiwijaya, et al.
Publicado: (2012)

MONITORING OF LONG-TERM ANTIVIRAL TREATMENT OF CHRONIC HEPATITIS B
por: A. A. Sukhoruk, et al.
Publicado: (2018)

IDENTIFICATION OF MUTATIONS OF RESISTANCE TO FLUOROQUINOLONES, AMINOGLYCOSIDES AND ETHAMBUTOL IN RIFAMPICIN-RESISTANT MYCOBACTERIUM TUBERCULOSIS
por: I. V. Bakshtanovskaya, et al.
Publicado: (2018)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
por: Meritxell Llorens-Revull, et al.
Publicado: (2021)

Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?
por: Lim TR
Publicado: (2014)

Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome
por: Omar A. Saldarriaga, et al.
Publicado: (2021)

NEW METHOD FOR DETERMINING HEPATITIS B VIRUS RESISTANCE MUTATIONS M204I/V TO NUCLEOS(T)IDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B
por: E. A. Elpaeva, et al.
Publicado: (2015)

SENSITIVITY OF 2018 KAZAKHSTAN INFLUENZA TYPE B VIRUSES TO ANTIVIRAL DRUGS
por: G. V. Lukmanova, et al.
Publicado: (2018)

GENETIC VARIANTS OF HEPATITIS B VIRUS IN PRIMARY DONORS IN ASTANA, KAZAKHSTAN
por: Yu. V. Ostankova, et al.
Publicado: (2017)

Experimental approbation of sheet metal magnetic permeability measurement systems
por: E.A. Chaplygin, et al.
Publicado: (2014)

RESULTS OF GENOTYPING HEPATITIS VIRUS B IN HBsAg-NEGATIVE BLOOD DONORS IN ASTANA, KAZAKHSTAN
por: Yu. V. Ostankova, et al.
Publicado: (2018)

Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals
por: Elabd NS, et al.
Publicado: (2021)

Hepatitis B virus and site-specific nucleases: effects of genetic modifications in CRISPR/Cas9 on antiviral activity
por: A. P. Kostyusheva, et al.
Publicado: (2019)

EFFICIENCY OF IMMUNOCORRECTION IN СHRONIC VIRAL HEPATITIS C PATIENTS TREATED BY ANTIVIRALS
por: L. P. Sklyar, et al.
Publicado: (2014)

HEPATITIS A PREVALENCE AMONG CHILDREN IN BOKE AND KINDIA PROVINCES (REPUBLIC OF GUINEA)
por: E. V. Esaulenko, et al.
Publicado: (2018)

Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
por: Yen-Chun Chen, et al.
Publicado: (2021)

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C
por: Naoki Kawagishi, et al.
Publicado: (2021)